CorMedix Inc. CRMD
CorMedix Inc. (Nasdaq: CRMD) is an infectious disease drug developer. Its lead program, DefenCath (taurolidine and heparin), is in Phase 3 for Reduction of catheter-related bloodstream infections in adult hemodialysis patients with a central venous catheter. Its next catalyst on record is REZZAYO (rezafungin): CorMedix is targeting to begin promotional efforts for REZZAYO in the new indication in H2 2027. (H2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: REZZAYO (rezafungin) — CorMedix is targeting to begin promotional efforts for REZZAYO in the new indication in H2 2027. (H2 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| DefenCath | CRBSI reduction in hemodialysis | small molecule | Approved |
| REZZAYO (rezafungin) | Candidemia and invasive candidiasis | small molecule | Approved |
| MINOCIN (minocycline) for Injection | Serious bacterial infections | small molecule | Approved |
| VABOMERE (meropenem and vaborbactam) | Complicated urinary tract infections / gram-negative infections | small molecule | Approved |
| KIMYRSA (oritavancin) | Gram-positive skin infections | small molecule | Approved |
| ORBACTIV (oritavancin) | Gram-positive skin infections | small molecule | Approved |
| BAXDELA (delafloxacin) | Bacterial infections | small molecule | Approved |
| TOPROL-XL (metoprolol succinate) | Cardiovascular | small molecule | Approved |
| REZZAYO prophylaxis | Prophylaxis of invasive fungal diseases in adult allogeneic HSCT patients | small molecule | Phase 3 |
Recent results and decisions
- Oct 19, 2026accepted FDA accepted for filing the sNDA for REZZAYO (rezafungin) for prophylaxis of invasive fungal disease with Priority Review; PDUFA target action date in Q1 2027.
the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) seeking approval of REZZAYO® (rezafungin for injection) for the prophylaxis of invasive fungal disease.
Filing - Apr 27, 2026met Phase 3 ReSPECT met primary endpoint of non-inferiority in fungal-free survival at Day 90: 60.7% rezafungin vs 59.0% standard antimicrobial regimen.
The ReSPECT study met its primary endpoint for FDA and EMA for fungal-free survival at Day 90 showing non-inferiority vs. SAR, with 60.7% fungal-free survival at Day 90 for rezafungin compared to 59.0% for standard antimicrobial regimen.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 infectious disease companies
- Gilead Sciences, Inc. GILD
- GSK plc GSK
- Moderna, Inc. MRNA
- Vaxcyte, Inc. PCVX
- Vir Biotechnology, Inc. VIR
- Novavax Inc NVAX
- Sinovac Biotech Ltd SVA
- Valneva SE VALN
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.